To determine whether this prognostic signature might independently predict the prognosis for CRC patients, we combined the clinical features (age, gender, tumor location, TNM stage, and KRAS mutation) with the risk scores of the prognostic signature in univariate and multivariate Cox regression analyses. The gene discussed is KRAS; the disease is neoplasm.